Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus
- PMID: 21969015
- PMCID: PMC3206147
- DOI: 10.1161/CIRCULATIONAHA.111.033894
Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus
Abstract
Background: Cardiac manifestations of neonatal lupus include conduction disease and, rarely, an isolated cardiomyopathy. This study was initiated to determine the mortality and morbidity of cardiac neonatal lupus and associated risk factors in a multi-racial/ethnic US-based registry to provide insights into the pathogenesis of antibody-mediated injury and data for counseling.
Methods and results: Three hundred twenty-five offspring exposed to maternal anti-SSA/Ro antibodies with cardiac neonatal lupus met entry criteria. Maternal, fetal echocardiographic, and neonatal risk factors were assessed for association with mortality. Fifty-seven (17.5%) died, 30% in utero. The probability of in utero death was 6%. The cumulative probability of survival at 10 years for a child born alive was 86%. Fetal echocardiographic risk factors associated with increased mortality in a multivariable analysis of all cases included hydrops and endocardial fibroelastosis. Significant predictors of in utero death were hydrops and earlier diagnosis, and of postnatal death were hydrops, endocardial fibroelastosis, and lower ventricular rate. Isolated heart block was associated with a 7.8% case fatality rate, whereas the concomitant presence of dilated cardiomyopathy or endocardial fibroelastosis quadrupled the case fatality rate. There was a significantly higher case fatality rate in minorities compared with whites, who were at a lower risk of hydrops and endocardial fibroelastosis. Pacing was required in 70%; cardiac transplantation was required in 4 children.
Conclusion: Nearly one fifth of fetuses who develop cardiac neonatal lupus die of complications predicted by echocardiographic abnormalities consistent with antibody-associated disease beyond the atrioventricular node. The disparity in outcomes observed between minorities and whites warrants further investigation.
Figures
Comment in
-
Ineffective therapy, underpowered studies, or merely too little, too late? Risk factors and impact of maternal corticosteroid treatment on outcome in antibody-associated fetal heart block.Circulation. 2011 Nov 1;124(18):1905-7. doi: 10.1161/CIRCULATIONAHA.111.061267. Circulation. 2011. PMID: 22042925 No abstract available.
References
-
- McCue CM, Mantakas ME, Tingelstad JB. Congenital heart block in newborns of mothers with connective tissue disease. Circulation. 1977;56:82–90. - PubMed
-
- Chameides L, Truex RC, Vetter V, Rashkind WJ, Galioto FM, Jr, Noonan JA. Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med. 1977;297:1204–1207. - PubMed
-
- Scott JS, Maddison PJ, Taylor PV, Esscher E, Scott O, Skinner RP. Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. N Engl J Med. 1983;309:209–212. - PubMed
-
- Reed BR, Lee LA, Harmon C, Wolfe R, Wiggins J, Peebles C, Weston WL. Autoantibodies to SS-A/Ro in infants with congenital heart block. J Pediatr. 1983;103:889–91. - PubMed
-
- Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol. 2005;26:16–21. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
